Evaluation of Clinical Effectiveness of Bioactive - Glass and Platelet - Rich Fibrin in the Management of Intrabony Defects - A Comparative Study

Abstract

Background: Platelet-Rich Fibrin (PRF), the second-generation platelet concentrate has various fringe benefits over other platelet concentrates. Just finite number of research works have concentrated on the utilization of PRF in combination with various kinds of bone grafts in intra-bony defects. Objective: The primary intention of this study was to determine the clinical and radiographical efficacy of Bioactive-glass with and without autologous PRF in the management of three-wall vertical defects. Methods: Twenty intrabony defects were arbitrarily chosen and treated either with Bioactive Glass (BG) alone or in mix with PRF (PRF/BG). Clinical parameters were documented preoperatively (baseline) and at six months post-operatively. Radiographic analysis was performed at baseline, third and sixth-month intervals. Results: The study outcome demonstrated that both treatment approaches were effectual. Significant decrease in the mean probing depth and gain in clinical attachment was observed in BG+PRF and BG groups as compared to baseline but was statistically insignificant at 6 months. (p=0.475, p=0.245 respectively). Radiographically, reduction in defect depth was significantly greater in BG+PRF group than BG group (p=0.007) at 6 months. Conclusion: Within the limitation of the current study, it is proposed that both treatment modalities are effective in the management of 3-wall intra-bony defects. The outcomes additionally uncovered that incorporation of PRF with BG has more successful and promising results. Hence in future, clinical trials with bigger sample size may be employed to further explore the potential benefits of PRF as a sole grafting material.